Glycoproteins (GPs) llblllla and lb/lX are principal targets of autoantibodies (autoAbs) in idiopathic thrombocytopenic purpura (ITP). Platelet-associated Abs against GPllb/llla primarily recognize discontinuous or nonlinear epitopes (Fujisawa et al, Blood 81:1284). This study focused on whether Abs against the extracellular domain of GPb/lX might react with short linear amino acid (aa) sequences of GPlba. Complementary DNAs (cDNAs) coding for two overlapping fragments of GPlba were amplified, cloned into pFLAG.2 plasmids, and expressed in Escherichia coli DH5a competent cells as FLAG fusion proteins, which were purified by anti-FLAG immunoaffinity chromatography. Of 16 selected I TP sera containing anti-GPlb/lX, 6 reacted in microtiter radioimmunoassays (RIAs) with recombinant protein fragment 2 (aas 240 t o 485); 1 also with fragment 1 (aas 1 HRONIC IDIOPATHIC thrombocytopenic purpura (ITP) is an acquired autoimmune disorder in which platelets are specifically targeted by autoantibodies (autoAbs) and destroyed in the reticuloendothelial system. The reason for otherwise healthy individuals developing antiplatelet autoAbs is unknown. Current treatment of ITP is primarily empirical, aimed at nonspecific immunosuppression or inhibition of reticuloendothelial function. Defining epitopes of ITP autoAbs may show homologies with autologous or environmental agents that could trigger autosensitization or cross-reactions. In addition, it may facilitate better design of therapies, such as use of immobilized peptides as Ab adsorbents or soluble peptides as specific competitive Ab inhibitors or tolerogens.
Glycoproteins (GPs) llblllla and lb/lX are principal targets of autoantibodies (autoAbs) in idiopathic thrombocytopenic purpura (ITP). Platelet-associated Abs against GPllb/llla primarily recognize discontinuous or nonlinear epitopes (Fujisawa et al, Blood 81:1284, 1993 ). This study focused on whether Abs against the extracellular domain of GPb/lX might react with short linear amino acid (aa) sequences of GPlba. Complementary DNAs (cDNAs) coding for two overlapping fragments of GPlba were amplified, cloned into pFLAG.2 plasmids, and expressed in Escherichia coli DH5a competent cells as FLAG fusion proteins, which were purified by anti-FLAG immunoaffinity chromatography. Of 16 selected I TP sera containing anti-GPlb/lX, 6 reacted in microtiter radioimmunoassays (RIAs) with recombinant protein fragment 2 (aas 240 t o 485); 1 also with fragment 1 (aas 1 HRONIC IDIOPATHIC thrombocytopenic purpura (ITP) is an acquired autoimmune disorder in which platelets are specifically targeted by autoantibodies (autoAbs) and destroyed in the reticuloendothelial system. The reason for otherwise healthy individuals developing antiplatelet autoAbs is unknown. Current treatment of ITP is primarily empirical, aimed at nonspecific immunosuppression or inhibition of reticuloendothelial function. Defining epitopes of ITP autoAbs may show homologies with autologous or environmental agents that could trigger autosensitization or cross-reactions. In addition, it may facilitate better design of therapies, such as use of immobilized peptides as Ab adsorbents or soluble peptides as specific competitive Ab inhibitors or tolerogens.
Platelet membrane glycoproteins (GPs) IIbnIIa and Ib/ IX appear to be the principal binding sites of I'P serum antibodies'-' and are targeted with about equal frequency?.' Antigenic determinants reactive with serum Abs are located on both cytosolic and extracellular domains of these GPs.'" Abs against cytosolic determinants do not bind to intact fresh platelets. Furthermore, they can be found in nonthrombocytopenic individuals who have recently recovered from a variety of disorders involving platelet de~truction,~ suggesting they are not pathogenic but arise ~econdarily.'-~ In contrast, autoAbs against extracellular GP epitopes can be eluted from ITP patients' platelets as well as adsorbed from ITP sera onto normal platelets. There is also strong evidence from clinical correlations that they have a pathogenic role in the disorder.'" '
Thus far, attempts to characterize extracellular GP epitopes of ITP Abs have focused on GPIIbnIIa. Most reactions of platelet-associated Abs (PAAbs) required an intact heterodimeric ~o m p l e x . '~~'~ In this study, we sought to define extracellular epitopes of GPIba, the major component of GPIblIX. GPIba contains 610 amino acids (aas), 485 of which are extrace1l~lar.l~ Our approach was to test reactivity of ITP sera against 2 large recombinant fragments of the extracellular domain of GPIba and then against small synthetic peptides chosen for their high antigenic indices within the most reactive recombinant fragment. Adsorption and competitive inhibition studies were performed to determine whether the peptide epitopes were present in native GPIba on the platelet surface.
MATERIALS AND METHODS
Study sera. Sera from 16 patients with chronic ITP were selected for study based on their reactivity against extracellular determinants of GPIb/IX by standard antigen capture immunobead assays and adsorption studies, as described previo~sly.~ Controls included 10 ITF' sera not containing anti-GPIb/IX and 20 sera from normal individuals. Patients with ITP met the diagnostic criteria of having thrombocytopenia with no underlying illness or abnormality that might account for it and of having normal or increased numbers of marrow megakaryocytes. All were adults with ITP for more than 2 years; 5 patients were male and 11 were females. A few sera were used fresh; the remainder had been stored up to 10 years in small aliquots at -20°C and were centrifuged at 11,OOOg for 10 minutes before use. None was subjected to more than one freeze-thaw.
Platelet preparation. Blood was drawn using a double syringe technique with a 19-gauge needle. EDTA was the anticoagulant.
Prostaglandin E, (3 pmoVL) was added. Platelet-rich plasma obtained by centrifugation at 18Og for 8 minutes was gel-filtered on Sepharose 2BI5 (Pharmacia, Uppsala, Sweden) using Tyrode's buffer (138 mmol/L NaCl, 2.9 mmoVL KCI, 12 mmoVL NaHCO,, 0.4 mmoVL NaH2P03, 0.1% glucose, pH 7.4) with 0.35% bovine serum albumin (BSA). Platelets were used the same day for Ab adsorption studies, flow cytometry, or sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Platelets for purified membrane 3790 HE ET AL and GP preparation were obtained by apheresis of normal volunteers at the Department of Transfusion Medicine, Clinical Center, National Institutes of Health (Bethesda, MD).
Platelet membrane preparation. Platelets were washed in phosphate-buffered saline (PBS), pH 7.4, containing 5 mmol/L EDTA (PBS-EDTA), loaded with glycerol, hypotonically lysed, and sedimented through a sucrose-density step gradient as previously described.I6 Membranes collected from the step interface were washed twice in PBS and used the same day for preparation of indirect eluates.
Eluate preparation. Platelet membranes were used instead of whole platelets to reduce nonspecific IgG and other proteins in indirect eluates. Forty milligrams of platelet membranes was incubated for 16 hours at 4°C with 40 mL of ITP or normal plasma anticoagulated with EDTA. Membranes were pelleted at 62,OOOg for 30 minutes, washed twice with PBS-EDTA, suspended in 5 mL of normal saline, acidified to pH 2.8 with 0.1 N HCI, rocked gently for 10 minutes, and repelleted. The supernatant was removed, neutralized to pH 6.5 with 0.01 N NaOH, and clarified by centrifugation at 10,OOOg for 15 minutes. Direct eluates were prepared similarly, starting with washed patient's platelets suspended in normal saline.
Flow cytometry. Fresh, unfixed, gel-filtered platelets were incubated with ITP or control eluates for 1 hour at 20°C. washed twice in flow buffer (PBS containing 0.5% BSA and 2.5 mmolL EDTA), and incubated for 1 hour with a U500 dilution of fluorescein isothiocyanate (F1TC)-labeled goat y-specific antihuman IgG (KirkegaardPerry, Gaithersburg, MD). Ten thousand cells were analyzed per test on a FACScan instrument (Becton Dickinson, San Jose, CA).
Glycocalicin preparation. Following a published method," approximately 20 U of washed platelets was incubated in 3 mol/L KC1 at 37°C for 30 minutes, and the platelet supernatant, after dialysis, was applied to a column of wheat germ lectin Sepharose 6-MB (Pharmacia). The eluate, obtained with 5% N-acetylglucosamine in PBS-0.5% EDTA, was subjected to molecular sizing on a column of Sepharose CL-4B (Pharmacia). Protein collected in fractions representing the molecular weight range for GC appeared as a single band at approximately 110 kD on Coomassie blue-stained SDS-PAGE and on an immunoblot developed with murine monoclonal anti-GPIb (clone SZ2; Immunotech, Westbrook, ME). The protein concentration of GC was measured by a bicinchoninic acid assay (Pierce, Rockford IL).
SDS-PAGE and protein immunoblotting. SDS-PAGE and protein immunoblotting were performed according to the methods of Laemmli'' and Bumette," respectively, using 7.5% gels (BioRad, Richmond, CA) and 0.45-pm nitrocellulose (Schleicher & Schuell, Keene, NH).
Ampl$cation of GPIba DNA fragments. Full-length 2,420-bp GPIba cDNA constructed in vector pVEGT was a gift from Dr Gerald J. Roth (University of Washington, Seattle Veteran's Administration Medical Center, Seattle, WA). Two overlapping fragments of GPIba cDNA were amplified by polymerase chain reaction (PCR)'" on an OmniGene thermocycler (Hybaid, Middlesex, UK). (5'CGGAATTCATGACCTCTAACGTGGCCAGTGTG-3'), and D, plify fragment 2. EcoRI restriction sites in primers A and C and Xho I sites in primers B and D are underlined. Thirty-five cycles were performed as follows: 1 minute at 95"C, 1 minute at 5 2 T , and 2 minutes at 72°C. Afterwards, a single final elongation step was performed at 72°C for 5 minutes. Samples were analyzed on 0.75% agarose gels stained with ethidium bromide and visualized under UV light.
Amplificates were subcloned into IBI Escherichia coli pFLAG.2 expression vectors (Eastman Chemical CO, New Haven, CT) that were transfected into E coli DH5a competent cells (GIBCO BRL, Gaithersburg, MD) by heat shock per the manufacturer's instructions. Successful cloning was confirmed by extensive restriction analysis. FLAG-fusion proteins were purified by immunoaffinity chromatography using monoclonal anti-FLAG M2 affinity gel (Eastman Chemical CO). Recombinant protein fragment I consisted of aas 1 to 247 and fragment 2 consisted of aas 240-485, each tagged at their N-terminal ends with the FLAG octapeptide. They were stored in buffer containing 50 mmovL Tris-HCI, 150 mmol/L NaCI, pH 7.4, at -20°C until used in radioimmunoassays (RIAs).
Peptides. Peptides were prepared by BioSynthesis, Inc (Lewisville, TX). The amino acid sequence of GPIba14." and its antigenicity index p l~t ,~'~'~ which was accessed through GenBank (Los Alamos, NM) using MacVector software (Eastman Kodak, New Haven, CT), were used as a basis for producing four synthetic peptides, designated P1 to P4 within fragment 2 (Fig 1) . The decapeptide, TKEQTTFPPR, contained the 9 aas that further localized the P2 (2lmer) epitope (see Results and Fig 6) ; one extra aa, arginine, was added to simplify the synthetic process, which is difficult for peptides with C-terminal prolines. The irrelevant peptide used as a negative control in this study had the following sequence: YGCKNFFWKTFTSC. All peptides were readily soluble in PBS, pH 7.4, and were stored at -20°C.
Radiolabeling Igs. Murine monoclonal antihuman IgG (clone 8A4; Immunotech, Westbrook, ME) was radiolabeled with Iz5I using Iodogen (Pierce, Rockford, IL) according to the manufacturer's directions. In a typical experiment, 0.2 mg of Ab was labeled. Ninetyfive percent of cpm was precipitable with 10% trichloroacetic acid, and the specific activity of the '251-protein was 1.0 to 2.0 pCi/pg.
RIA. Immulon 4 polystyrene removawell strips (Dynatech,
Chantilly, VA) were incubated overnight at 4°C with 100 pL per well of purified protein or peptide that had been diluted to a concentration of IO pg/mL in coating buffer, pH 9.5 (Kirkegaard-Perry). Wells were washed three times with PBS containing 0.05% Tween-20, pH 7.4 (PBS-T), blocked for 1 hour at 20°C with 2% BSA in PBS-T, washed three times, incubated for 1 hour with sera diluted 1/10 or with direct eluates from 5 X lo6 platelets, washed three times, incubated for 1 hour with 50 ng '251-murine monoclonal antihuman IgG per well, washed three times, and counted. Samples were always tested in triplicate. Tests were considered positive if the average cpm exceeded by 3 standard deviations (SDs) the average cpm of 3 or more control samples tested on the same plate. Results with wells coated with an irrelevant peptide did not differ significantly for ITP sera and normal control sera.
Adsorption of anti-P2 by intact platelets. Fresh, gel-filtered platelets were aliquoted into 1.5 mL microfuge tubes in total quantities ranging from 2.5 X IO' to 1 X 10' and pelleted by centrifugation at 1,OOOg for 10 minutes. Supernatants were removed and platelets were suspended into 100 pL of a 1/10 dilution of test serum in PBS-T. After incubation for 60 minutes at 20°C, platelets were removed and sera were tested for reactivity with P2 by RIA. Results were compared with anti-P2 reactions of unadsorbed sera. Control adsorptions consisted of 1 X 10' 0-negative washed erythrocytes suspended in 100 pL of a 1/10 dilution of each test serum in PBS-T.
Competition between GC in solution and immobilized P2 for anti-P2. One-hundred microliter aliquots of a 1/10 dilution of ITP se- Adsorption of anti-GC by immobilized P2. One hundred microliters of a 1/20 dilution of serum in PBS-T were incubated for 1 hour at 20°C in a well precoated with P2, as described above, and then transferred to another identical well for a second 1 hour of adsorption. Reactivity of adsorbed serum with GC was then tested by RIA and compared with that of unadsorbed serum.
Detection of anti-P2 and platelet-bindable IgG in platelet eluates.
Eluates were checked for anti-P2 activity by RIA. Table 1 . Each peptide overlapped the preceding one by 9 aa residues, with an offset of 6 aas. Most peptides were easily solubilized in 40% acetonitrile/water solution and stored at -70°C until used. Peptides not soluble in this manner ( nos. 1, 2, 8, 13, 14, 19, 20, 28, 30 , 31, 32, and 39) were dried down and solubilized in 100% dimethyl sulfoxide (DMSO). Microtiter plates were coated with 100 pL per well of a 5 pg/mL solution of streptavidin (affinity-purified, salt-free; Sigma, St Louis, MO) and evaporated to dryness overnight at 37°C. A standard en- zyme-linked immunosorbent assay (ELISA) protocol supplied by Chiron was used. One hundred microliters of peptide at approximately 12 pg/mL was coated per well. All peptides were coated in duplicate on wells of a single microtiter plate that was then exposed to one serum. Sixteen lTP and 11 noma1 sera were tested, each at 11100 dilution. The amount of 2 ITP and 5 control eluates tested were derived from approximately 5 X lo6 platelets. Peroxidaselabeled goat antihuman IgG was used at 1/2,000 dilution, and absorbance was measured at 410 nm with a Dynatech MR 650 plate reader after addition of ABTS substrate (Kirkegaard-Perry).
RESULTS
Reactions of sera with immobilized GC. Of 16 ITP sera containing anti-GPIbW by antigen capture assays, 6 (no. 1 through 6) reacted with purified GC in RIAs. Cpms of positive samples exceeded by 3 SDs the mean of 3 normal sera run in triplicate concurrently. For normal sera, the ratio of the mean + 3 SDs divided by the mean (control ratio) was 1.5. A total of 16 normal sera were tested to calculate this ratio. Ratios for positive sera (mean patient's cpm divided by the normal mean) ranged from 2 to 5.2. None of the six positive sera, used at 1/20 dilution, elicited reactions in immunoblots with GPIb from solubilized platelets or with purified GC. Reactions of sera with recombinant GPIba protein fragments. When recombinant GPIba protein fragment 1 (aas 1 to 247) and fragment 2 (aas 240 to 485) were used as target antigens (Ags) in RIAs for the 16 ITP study sera, the same 6 that reacted with GC reacted with fragment 2. One (no. 6) also reacted with fragment 1. The control ratio was 1.4, based on determinations with 18 normal sera, and the ratios for positive sera ranged from 2 to 5.3. On the basis of these results, attention was focused on epitope mapping fragment 2.
Reactions of sera and direct eluates with synthetic GPIba peptides (P1 to P4). When the four synthetic peptides P1
to P4 shown in Fig 1 were plated as target Ags in RIAs, sera no. 1 through 6 reacted with P2; serum 3 also reacted with P4. Results are summarized in with P2 compared with 5 direct eluates of normal platelets ( Table 2 ). To further substantiate that the specificity of reactions with P2 was the same as reactions with intact platelets and GC, adsorption and competitive inhibition studies were performed.
Adsorption of anti-P2 by intactplatelets. Figure 2 shows the adsorption of anti-P2 from sera no. 1, 2, and 3 by intact platelets. Anti-P2 was greater than 80% adsorbed from 10 pL of serum by 5 x IO' to IO9 platelets; anti-P2 was not adsorbed in detectable amounts from these sera by 10' 0-negative erythrocytes.
Inhibition of anti-P2 by purified GC in solution. Figure  3 shows results of adding purified GC to sera no. 1, 2, and 3 before reacting them with immobilized P2. Anti-P2 was decreased 60% to 85% by the presence of 9 X m o m GC (10 &IO pL). The amount of anti-P2 competitively inactivated by GC was less than the amount of anti-P2 removed by adsorption with platelets containing equivalent amounts of GC (see Fig 2; 2 X lo8 platelets contain approximately 1 pg GC).
Inhibition of anti-P2 and anti-GC by P2 in solution. Figure 4 shows that anti-P2 activities (open symbols) in sera no. 1 and 2 were inhibited 40% to 75% by 2.5 pg P2/100 pL (8.6 X mol/L) of 1/10 diluted serum. P2 in solution at the same concentration inhibited anti-GC activities (solid symbols) by about 20%, and inhibition increased to only 30% by a 10-fold further increase in P2 concentration. In m o m had no effect on binding of anti-P2 to platelets.
Adsorption of anti-GC by immobilized P2. Figure 5 shows adsorption of anti-GC of from sera no. 1, 2, and 6 by immobilized P2. Anti-GC was fully removed from sera no. 1 and 2 but was only partially removed from serum no. 6, which presumably reflects the presence of residual Ab against fragment 1 and/or other untested epitope(s) on fragment 2 in the sample after Ab against P2 was adsorbed.
Platelet-bindable IgG and anti-P2 in platelet eluates. Normal platelets had increased surface-bound IgG after incubation with indirect and direct ITP eluates from patients no. 1 and 2 as shown by a significant increase in their fluorescence profiles compared with platelets incubated with control eluates (data not shown). Both patients' eluates contained anti-P2 (Table 2) .
Epitope mapping of fragment 2 using a panel of overlapping peptides. Figure 6 shows ELISA reactions of sera no. l through 6 and of 2 direct eluates from patients no. 1 and 2 with sequential 15-mer peptides of fragment 2. Typical controls are also shown. Each serum and platelet eluate reactive with P2 reacted with peptides no. 16 and 17. The direct eluate of patient no. l reacted with peptides no. 26 and 27, which are in the domain of P4, but serum from this patient did not react with P4. Serum from patient no. 3 reacted with P4, but not with any of its smaller constituitive peptides (nos. 25 to 29). As seen in Table 1 , the 9 aa sequence, TKEQTTFPP, was common to peptides no. 16 and 17. When synthesized as a decapeptide with R at the carboxy-terminal end, it reacted only with sera no. 1 and 4. Ratios for positive sera were 2.2 and 2.3, respectively, compared with the control ratio of 1.5 obtained with 20 normal sera, all used in the same experiment with ITP sera. Preincubation of sera no. 1 through 6 with immobilized P2 completely removed activity against peptides no. 16 and 17.
DISCUSSION
Knowledge of ITP autoAbs has recently been more clearly defined by use of Ag capture techniques to identify specific targeted G P s . ' .~~ These tests offer increased sensitivity over standard ELISAs and immunoblots, most likely by maintaining native conformations of antigenic GP determinants. From extensive use of these assays,"' the patterns of reaction 1, 2, and 3) was incubated for 1 hour with various numbers of fresh gel-filtered platelets, after which anti-P;L activity of the supernatant was measured by RIA. These values were compared with anti-P2 activities in the same sera before adsorption.
For Internal epitopes of plasma Abs have been mapped to short C-terminal cytoplasmic peptides of GPIIIa'" and GPIba,' but Abs specific for these epitopes appear to be secondarily stimulated by excessive platelet destruction and are not pathogenically significant.'" On the other hand, PAAbs that react with external epitopes of GPIIbfiIIa quanti- Antibodies against globular proteins typically react with discontinuous (nonlinear or assembled) epitopes that are dependent on protein folding.26 For instance, reactions of most PAAbs against GPIIbflIIa are dependent on an intact heterodimeric complex.'* Linear peptides each of approximately 200 aas, together spanning the full length of GPIIIa, reacted with only 2 of 32 anti-GPIIbnIIa PAAbs.13 Similarly, nonlinear (higher order) structure was necessary for antigenicity of a 50-kD chymotryptic fragment of GPIIIa that reacted in the native state, but not after disulfide reduction, with serum Abs in 48% of chronic ITP patients and in some patients with secondary and nonimmune thrombo~ytopenias.~'
In our study, 6 (38%) of 16 ITP sera that were known to contain anti-GPIb/IX reacted with GC, which accounts for almost all of the extracellular domain of GPIba. The other I O sera presumably had specificitites for GPIb,, GPIX, a complex-dependent epitope, or an epitope on the short segment of GPIba remaining after GC cleavage.
To map glycocalicyl epitopes, we first studied Ab reactions with two recombinant fragments of GC that lacked For personal use only. on October 3, 2017. by guest www.bloodjournal.org From (Fig  l) , the 21-aa P2 reacted with all 6 sera and the 24-aa P4 also reacted with one of these sera. P2 and P4 are located within the macroglycopeptide domain of GPIba, where there is minimal folding or tertiary structure because of constraints imposed by numerous proline residues and 0-linked glycosylations as well as lack of cysteine r e s i d~e s . '~.~~,~~ The P2 epitope was further defined by Ab reactions with a panel of overlapping 15mer peptides (Fig 6) . All positive sera and platelet eluates from 2 of the patients whose sera were positive reacted with peptides no. 16 and 17, which share 9 aas, TKEQTTFPP. AntLP2 accounted for all anti-GC activity directed at the fragment 2 domain in 2 of 3 sera tested ( Fig  5) . Purified GC effectively competed for anti-P2 (Fig 3) ; adsorption of sera with fresh, gel-filtered platelets removed anti-P2 activity (Fig 2) ; and direct eluates of patients' platelets contained anti-P2. P2 is therefore expressed on native GC and is accessible on the surface of platelets. Evidence that ITP Abs often have low affinity is the low number of specific anti-GP Abs attached per platelet in the presence of excess Ab despite high-density expression of reactive GPs.~ Full adsorption of anti-P2 required approximately 25 to 100 times more platelets than necessary to completely adsorb many serum platelet-specific alloAbs," suggesting that anti-P2 Abs may have relatively low affini- m o m was ineffective in inhibiting binding of anti-P2 to platelets, was weakly effective in inhibiting reactions with immobilized GC, and was most effective in inhibiting reaction with immobilized P2 (Fig 4) . Anti-P2 appears to have the highest affinity when the epitope is on platelets, less when on purified GC, and least for P2 itself. This phenomenon has been described for certain antimyoglobin antibodies against continuous determinants and has been attributed to the low probability of short peptides in solution assuming conformations similar to those of the native protein.32 The decapeptide defining the epitope has less affinity for the Ab than P2 in that it reacted weakly with only 2 of the 6 sera that were positive with P2. Thus, P2 or the decapeptide would not be effective in vivo as competitors to prevent attachment of ITP Abs to platelets. However, immobilized P2 (21-mer) was effective in removing specific Abs from patient's plasma. This may be attributable to an increased apparent affinity of antibody for antigen locally concentrated on a solid surface.33
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The direct eluate of patient no. 1 reacted with peptides no. 26 and 27 in the domain of P4, but her serum did not, possibly because low-titer Abs were present only on platelets. Serum Abs from patient no. 3 reacted with P4 but not with peptides no. 25 through 29 in the domain of P4, perhaps due to lesser affinity for smaller peptides.
Unlike anti-GC autoAbs in one case of acquired BernardSoulier syndrome,34 there is no indication from a clinical standpoint that autoAbs against P2 or P4 cause a functional platelet defect. This is consistent with the fact that the P2 and P4 sequences are distant from the hinge region where von Willebrand factor binds (aa 269 to 287 )21.35 as well as from a high-affinity thrombin binding site (aa 271-284).36 P2 and P4 are distinct from the KO (HPA-2) alloantigen, which is determined by a ThrMet polymorphism at aa 145,37 and from binding sites of many quinine/quinidine-dependent Abs that appear to be located adjacent to the plasma membrar~e.~' The complement-fixing autoAb against GPIbhX found in one unusual case of ITP would not have been directed against P2 or P4 because the Ab did not react with GC3'
Epitope mapping of platelet membrane GPs reactive with ITP autoAbs can potentially provide insight into structurally similar autologous and/or environmental antigens that underlie the autoimmune response. It is noteworthy that the macroglycopeptide region of GPIba contains structural homolgies to mucins from various species, being rich in serine, threonine, and p r~l i n e . '~.~' ,~~ Fifteen known proteins with partial homology to the nonapeptide, as defined by 6 matched and 3 mismatched aas, were identified through GenBank. Unique among the 15 was avian influenza A virus hemagglutinin (strain A/turkey/ontario) that contained 6 matching aas ordered precisely as those in the nonapeptide (TKEQITLYK P2 in solution at a concentration as high as 1.7 X v TKEQTTFFP).40 The particular domain containing this 6-aa stretch is not one that is highly conserved among the 13 known hemagglutinin A serotypes,40 which include human strains. Therefore, it would be conjectural to place significance in the epitope similarity between GPIba and this influenza virus with regard to ITP.
What relevance does anti-P2 have in ITP? Our studies suggest that anti-P2 does react with a native extracellular antigen and that anti-P2 Abs are both in plasma and on platelets and can be removed from plasma by adsorption with immobilized P2, G C , or platelets. It remains to be determined how anti-P2 varies with disease activity, how often it occurs clinically, whether it is a dominant Ab among the numerous anti-GPs that arise in ITP, and whether its removal or competitive inactivation can ameliorate the disease.
